161 related articles for article (PubMed ID: 8946471)
41. Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.
Bordet R; Broly F; Destée A; Libersa C; Lafitte JJ
Clin Neuropharmacol; 1996 Jun; 19(3):213-21. PubMed ID: 8726540
[TBL] [Abstract][Full Text] [Related]
42. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population.
Tateishi T; Chida M; Ariyoshi N; Mizorogi Y; Kamataki T; Kobayashi S
Clin Pharmacol Ther; 1999 May; 65(5):570-5. PubMed ID: 10340923
[TBL] [Abstract][Full Text] [Related]
43. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
44. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
[TBL] [Abstract][Full Text] [Related]
45. Debrisoquine hydroxylase and Parkinson's disease.
Kondo I; Kanazawa I
Adv Neurol; 1993; 60():338-42. PubMed ID: 8420147
[TBL] [Abstract][Full Text] [Related]
46. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Raimundo S; Toscano C; Klein K; Fischer J; Griese EU; Eichelbaum M; Schwab M; Zanger UM
Clin Pharmacol Ther; 2004 Aug; 76(2):128-38. PubMed ID: 15289790
[TBL] [Abstract][Full Text] [Related]
47. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.
Marez D; Sabbagh N; Legrand M; Lo-Guidice JM; Boone P; Broly F
Pharmacogenetics; 1995 Oct; 5(5):305-11. PubMed ID: 8563771
[TBL] [Abstract][Full Text] [Related]
48. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
49. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
50. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
51. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients.
Dandara C; Masimirembwa CM; Magimba A; Sayi J; Kaaya S; Sommers DK; Snyman JR; Hasler JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):11-7. PubMed ID: 11372584
[TBL] [Abstract][Full Text] [Related]
52. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population.
Kiyotani K; Shimizu M; Kumai T; Kamataki T; Kobayashi S; Yamazaki H
Eur J Clin Pharmacol; 2010 Oct; 66(10):1065-8. PubMed ID: 20700584
[TBL] [Abstract][Full Text] [Related]
53. [Allele specific amplification for CYP2D6 gene related to intermediate metabolizer in Chinese subjects].
Chen B; Cai WM; Ling SS
Yao Xue Xue Bao; 2001 Feb; 36(2):88-91. PubMed ID: 12579870
[TBL] [Abstract][Full Text] [Related]
54. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
55. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6.
Toscano C; Raimundo S; Klein K; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):767-70. PubMed ID: 17001296
[TBL] [Abstract][Full Text] [Related]
56. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
[TBL] [Abstract][Full Text] [Related]
57. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
58. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.
Mura C; Gerard N; Vincent-Viry M; Galteau MM; Jacqz-Aigrain E; Krishnamoorthy R
Br J Clin Pharmacol; 1993 Feb; 35(2):161-5. PubMed ID: 8095148
[TBL] [Abstract][Full Text] [Related]
59. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution.
Daly AK; Leathart JB; London SJ; Idle JR
Hum Genet; 1995 Mar; 95(3):337-41. PubMed ID: 7868129
[TBL] [Abstract][Full Text] [Related]
60. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.
Kimura S; Umeno M; Skoda RC; Meyer UA; Gonzalez FJ
Am J Hum Genet; 1989 Dec; 45(6):889-904. PubMed ID: 2574001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]